PENUMBRA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 205.6 USD | -0.28% |
|
+1.87% | -18.26% |
Presenter SpeechJoanne Wuensch (Analysts)Well, welcome, everybody. Long day. Hello. I'm Joanne...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
206.2
USD
Average target price
280.1
USD
Spread / Average Target
+35.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.26% | 7.98B | |
| +72.69% | 12.34B | |
| +15.52% | 7.19B | |
| +2.18% | 5.81B | |
| +6.51% | 5.04B | |
| +21.99% | 4.31B | |
| -20.27% | 4.03B | |
| -41.42% | 2.21B | |
| +0.87% | 1.99B | |
| +2.93% | 1.87B |
- Stock Market
- Equities
- PEN Stock
- News Penumbra, Inc.
- Transcript : Penumbra, Inc. Presents at Citi’s 2022 Virtual Healthcare Conference, Feb-24-2022 01
